Deep Bispecific Antibody Expertise
Leverage deep expertise across major bsAb formats to accelerate discovery from target validation to PCC in as little as 6 months, backed by 110+ bispecific antibody programs and multiple clinical-stage assets.
Monoclonal and Bispecific Solutions
Monoclonal and bispecific antibodies are transforming modern therapeutics, but development remains complex and resource intensive. ProBio streamlines the journey from discovery to commercialization with integrated antibody discovery, CMC development, and GMP manufacturing solutions.
Monoclonal and bispecific antibodies are among today's most successful therapeutic modalities, driving breakthroughs across oncology, autoimmune diseases, and other complex indications.
Backed by deep expertise in antibody discovery, process development, CMC, and commercial manufacturing, ProBio delivers integrated solutions that help accelerate development, reduce risk, and support long-term commercial success.
End-to-End Monoclonal and Bispecific Antibody Development
Accelerating Biologics with Confidence
Accelerated Path to IND
Accelerate antibody development with ExpressCMC and proven cell line development expertise, delivering industry-leading titers of 7.5 g/L for mAbs and 7 g/L for bsAbs on average while advancing programs from DNA to tox batch in just 4 months.
Clinical to Commercial Manufacturing
Scale confidently with GMP manufacturing from 50-2000 L, process characterization and validation, and BLA-enabling CMC support designed for long-term commercial readiness.
110+ bsAb Programs | PCC in 6 Months | DNA-to-Tox in 4 Months | 50-2000 L GMP Manufacturing.
Applications and Use Cases
HAND
BOOK
Optimized Cell Line Development
Strategies for Bispecific Antibody Manufacturing.
FLYER
ExpressCMC: 4 Months to Tox Batch
Smarter Antibody Discovery and Rapid Cell Line Development.
FLYER
BLA Service
Late Stage Process Development and Commercial Manufacturing Services.
Frequently Asked Questions
